- Focus on DMX-1001, a neuroplastogen therapy for Alcohol Use Disorder
- Neuroplastogen mechanism shared with psychedelics, promoting neural repair
- Collaboration aims to advance research, shape policy, and enhance access for novel addiction treatments
MIAMI, Fla – June 19, 2025 – DemeRx, a clinical-stage biotechnology company developing next-generation addiction medicines, is pleased to announce its membership in the Medical Psychedelics Working Group (MPWG), a consortium of experts, academics, researchers, and policy specialists dedicated to enabling safe and accessible psychedelic medicine.
DemeRx is focused on advancing its lead candidate, DMX-1001 (oral noribogaine), for the treatment of Alcohol Use Disorder (AUD), a condition affecting 29 million people in the U.S. DMX-1001 enhances neuroplasticity to potentially repair neural circuits damaged by chronic heavy drinking, offering a disease-modifying approach beyond existing symptom-focused treatments.
Joining the MPWG aligns with DemeRx’s mission to transform addiction therapeutics by collaborating with leading minds in the field of novel treatments for brain disorders. This membership is expected to facilitate crucial dialogue on regulatory pathways and broader acceptance of neuroplastogen-based therapies for substance use disorders.
“We are excited to join the Medical Psychedelics Working Group and collaborate with its esteemed members. Our work with DMX-1001, a neuroplastogen with a mechanism shared by psychedelics, represents a paradigm shift in treating addiction by focusing on neuronal repair,” said Deborah C. Mash PhD, CEO and Founder of DemeRx. “We believe that by working alongside the MPWG, we can contribute to the vital efforts in driving research, addressing regulatory challenges, and ultimately bringing effective, innovative treatments like ours to patients in need.”
Professor Jo Neill, Chair of the Medical Psychedelics Working Group, commented: “We welcome DemeRx to the MPWG. Their focus on noribogaine, a molecule demonstrating neuroplastogenic properties, highlights the expanding landscape of treatments for brain disorders that share mechanisms with classical psychedelics. Industry partners like DemeRx are crucial to our goal of translating cutting-edge science into accessible medical therapies. We look forward to their contributions to our discussions on research, policy, and patient access.”
DemeRx has completed a Phase 1b clinical trial for DMX-1001 in healthy volunteers and plans a Phase 2 trial in AUD patients in 2026.
Membership in the MPWG provides opportunities for industry partners to engage in scientific research, collaborate with regulators, promote education, and network with key stakeholders in the psychedelic medicine field. This collaboration is expected to support DemeRx’s efforts to navigate the evolving landscape of addiction treatment and contribute to broader acceptance of novel therapeutic approaches.
About DemeRx, Inc.
DemeRx, Inc. is a pioneering clinical-stage biopharmaceutical company committed to the discovery and development of innovative medications for addiction treatment. Leveraging advanced scientific research and strategic clinical initiatives, DemeRx focuses on DMX-1001 (noribogaine) as a groundbreaking solution for alcohol use disorder. Headquartered in Miami, Florida, DemeRx is dedicated to transforming addiction therapeutics and improving outcomes for individuals facing substance use disorders.
For more information, visit demerx.com